First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

202165 citationsJournal Articlegold Open Access

Authors

Seyed Pairawan · The University of Texas MD Anderson Cancer Center

Ming Zhao · The University of Texas MD Anderson Cancer Center

Erkan Yuca · The University of Texas MD Anderson Cancer Center

Allen Annis · Aileron (United States)

Kurt W. Evans · The University of Texas MD Anderson Cancer Center

David Sutton · Aileron (United States)

Luis A. Carvajal

Abstract

The significant synergy observed with ALRN-6924 in combination with chemotherapeutic agents supports further evaluation in patients with hormone receptor-positive breast cancer.

Topics & Keywords

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Breast Cancer Research

Volume 23, Issue 1, pp. 29-29

DOI: 10.1186/s13058-021-01406-x

Field-Weighted Citation Impact: 4.47